XENE XENON PHARMACEUTICALS INC revenue, earnings and financials

For the quarter ended June 30, 2026, XENON PHARMACEUTICALS INC reported revenue of $0, net income of −$111M and diluted EPS of −$1.11; over the last four quarters revenue was $0 and net income −$409M; for the fiscal year ended December 2025 revenue was $7.50M.

XENE annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $7.50M, gross profit n/a, operating income −$373M, net income −$346M (margin -4612.1%), EPS −$4.36
• Fiscal year ended Dec 2024: revenue $0, gross profit n/a, operating income −$279M, net income −$234M (margin n/a), EPS −$3.01
• Fiscal year ended Dec 2023: revenue $0, gross profit n/a, operating income −$214M, net income −$182M (margin n/a), EPS −$2.73
• Fiscal year ended Dec 2022: revenue $9.43M, gross profit n/a, operating income −$129M, net income −$125M (margin -1328.9%), EPS −$2.06
• Fiscal year ended Dec 2021: revenue $18.4M, gross profit n/a, operating income −$79.0M, net income −$78.9M (margin -427.8%), EPS −$1.77

XENE quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $0, net income −$111M, EPS −$1.11
• Quarter ended Mar 31, 2026: revenue $0 (down 100.0% year over year), net income −$102M, EPS −$1.17
• Quarter ended Dec 31, 2025 (from the annual report): revenue $0, net income −$105M, EPS −$1.31
• Quarter ended Sep 30, 2025: revenue $0, net income −$90.9M, EPS −$1.15
• Quarter ended Jun 30, 2025: revenue $0, net income −$84.7M, EPS −$1.07
• Quarter ended Mar 31, 2025: revenue $7.50M, net income −$65.0M, EPS −$0.83
• Quarter ended Dec 31, 2024 (from the annual report): revenue $0, net income −$65.7M, EPS −$0.83
• Quarter ended Sep 30, 2024: revenue $0, net income −$62.8M, EPS −$0.81
• Quarter ended Jun 30, 2024: revenue $0, net income −$57.9M, EPS −$0.75
• Quarter ended Mar 31, 2024: revenue $0, net income −$47.9M, EPS −$0.62
• Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$44.7M, EPS −$0.65
• Quarter ended Sep 30, 2023: revenue n/a, net income −$48.5M, EPS −$0.73
• Quarter ended Jun 30, 2023: revenue n/a, net income −$47.5M, EPS −$0.72
• Quarter ended Mar 31, 2023: revenue n/a, net income −$41.7M, EPS −$0.63
• Quarter ended Dec 31, 2022 (from the annual report): revenue $0 (down 100.0% year over year), net income −$37.4M, EPS −$0.59
• Quarter ended Sep 30, 2022: revenue $132K (down 98.4% year over year), net income −$37.2M, EPS −$0.57
• Quarter ended Jun 30, 2022: revenue $536K (down 75.8% year over year), net income −$31.2M, EPS −$0.55
• Quarter ended Mar 31, 2022: revenue $8.77M (up 101.1% year over year), net income −$19.7M, EPS −$0.35
• Quarter ended Dec 31, 2021 (from the annual report): revenue $3.74M, net income −$25.6M, EPS −$0.48
• Quarter ended Sep 30, 2021: revenue $8.12M, net income −$15.4M, EPS −$0.36

XENE cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$279M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$181M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$151M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$101M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$69.5M, share buybacks n/a

XENE balance sheet

• Jun 30, 2026: cash $120M, total assets $1.30B, total liabilities $53.4M, shareholders' equity $1.24B
• Mar 31, 2026: cash $546M, total assets $1.39B, total liabilities $49.0M, shareholders' equity $1.34B
• Dec 31, 2025: cash $199M, total assets $633M, total liabilities $51.4M, shareholders' equity $582M
• Sep 30, 2025: cash $105M, total assets $608M, total liabilities $48.3M, shareholders' equity $560M
• Jun 30, 2025: cash $135M, total assets $674M, total liabilities $40.3M, shareholders' equity $634M
• Mar 31, 2025: cash $117M, total assets $743M, total liabilities $39.3M, shareholders' equity $704M
• Dec 31, 2024: cash $143M, total assets $798M, total liabilities $43.2M, shareholders' equity $755M
• Sep 30, 2024: cash $87.6M, total assets $836M, total liabilities $38.1M, shareholders' equity $798M

What is XENE's revenue?

XENON PHARMACEUTICALS INC reported $0 of revenue over its last four quarters, through June 30, 2026.

Is XENE profitable?

No. XENON PHARMACEUTICALS INC lost $409M over the last four quarters.

What is XENE's EPS?

Diluted earnings per share over the last four quarters were −$4.74; −$1.11 in the latest quarter.

XENE ownership and insider trades · All stocks